艾司氯胺酮对腹腔镜手术女性患者术后睡眠质量的影响

注册号:

Registration number:

ChiCTR2500113859 

最近更新日期:

Date of Last Refreshed on:

2025-12-30 14:08:10 

注册时间:

Date of Registration:

2025-12-04 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

艾司氯胺酮对腹腔镜手术女性患者术后睡眠质量的影响

Public title:

Effect of esketamine on postoperative sleep quality in female patients undergoing laparoscopic surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

艾司氯胺酮对腹腔镜手术女性患者术后睡眠质量的影响

Scientific title:

Effect of esketamine on postoperative sleep quality in female patients undergoing laparoscopic surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

杜瑞 

研究负责人:

杜瑞 

Applicant:

Du Rui 

Study leader:

Du Rui 

申请注册联系人电话:

Applicant telephone:

+86 152 6824 3201

研究负责人电话:

Study leader's
telephone:

+86 152 6824 3201

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

26100559@qq.com

研究负责人电子邮件:

Study leader's E-mail:

26100559@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省湖州市吴兴区东街2号

研究负责人通讯地址:

浙江省湖州市吴兴区东街2号

Applicant address:

No. 2, Dongjie Street, Wuxing District, Huzhou, Zhejiang

Study leader's address:

No. 2, Dongjie Street, Wuxing District, Huzhou, Zhejiang

申请注册联系人邮政编码:

Applicant postcode:

313000

研究负责人邮政编码:

Study leader's postcode:

313000

申请人所在单位:

湖州市妇幼保健院

Applicant's institution:

Huzhou Maternity & Child Health Care Hospital

研究负责人所在单位:

湖州市妇幼保健院

Affiliation of the Leader:

Huzhou Maternity & Child Health Care Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025-J-092

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

湖州市妇幼保健院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Huzhou Maternity & Child Health Care Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-11-30 00:00:00

伦理委员会联系人:

周知音

Contact Name of the ethic committee:

Zhou Zhiyin

伦理委员会联系地址:

浙江省湖州市吴兴区东街2号

Contact Address of the ethic committee:

No. 2, Dongjie Street, Wuxing District, Huzhou, Zhejiang

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 572 203 0395

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

湖州市妇幼保健院

Primary sponsor:

Huzhou Maternity & Child Health Care Hospital

研究实施负责(组长)单位地址:

浙江省湖州市吴兴区东街2号

Primary sponsor's address:

No. 2, Dongjie Street, Wuxing District, Huzhou, Zhejiang

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

湖州

Country:

China

Province:

Zhejiang

City:

Huzhou

单位(医院):

湖州市妇幼保健院

具体地址:

浙江省湖州市吴兴区东街2号

Institution
hospital:

Huzhou Maternity & Child Health Care Hospital

Address:

No. 2, Dongjie Street, Wuxing District, Huzhou, Zhejiang

经费或物资来源:

自筹

Source(s) of funding:

Self- raising fund

研究疾病:

睡眠障碍  

Target disease:

Dyssomnia

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究旨在探讨在麻醉诱导期静脉注射艾司氯胺酮是否能够改善腹腔镜手术女性患者术后的睡眠质量,并评估其对镇痛效果及安全性的影响。  

Objectives of Study:

The purpose of this study was to investigate whether intravenous injection of esketamine during anesthesia induction can improve the postoperative sleep quality of female patients undergoing laparoscopic surgery, and to evaluate its effect on analgesia and safety.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

既往有精神疾病或慢性疼痛病史,长期服用镇静类药物或阿片类药物,对研究药物过敏者,BMI≥30 kg/m2。

Exclusion criteria:

Patients with a history of mental illness or chronic pain, long-term use of sedatives or opioids, and allergy to the study drug, BMI >=30 kg / m2.

研究实施时间:

Study execute time:

From 2025-12-10 00:00:00 To 2026-04-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-12-10 00:00:00 To 2026-04-30 00:00:00

干预措施:

Interventions:

组别:

对照组(C组)

样本量:

50

Group:

Control group ( group C )

Sample size:

干预措施:

C组于麻醉诱导时组给予静脉注射与S组艾司氯胺酮等容量生理盐水

干预措施代码:

Intervention:

Group C was given intravenous injection of normal saline with the same volume of esketamine as group S during anesthesia induction.

Intervention code:

组别:

艾司氯胺酮组(S组)

样本量:

50

Group:

Esketamine group ( S group )

Sample size:

干预措施:

S组于麻醉诱导时加用艾司氯胺酮0.3 mg/kg静脉注射

干预措施代码:

Intervention:

In group S, esketamine 0.3 mg / kg was intravenously injected during anesthesia induction.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

湖州 

Country:

China

Province:

Zhejiang

City:

Huzhou

单位(医院):

湖州市妇幼保健院 

单位级别:

三甲 

Institution
hospital:

Huzhou Maternity & Child Health Care Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后1、3、7 d的匹兹堡睡眠质量指数(PSQI)评分

指标类型:

主要指标

Outcome:

The Pittsburgh Sleep Quality Index ( PSQI ) scores at 1, 3 and 7 days after operation were recorded.

Type:

Primary indicator

测量时间点:

术后第1、3、7天

测量方法:

使用PSQI量表

Measure time point of outcome:

On the 1st, 3rd and 7th days after the operation

Measure method:

指标中文名:

术中舒芬太尼总用量

指标类型:

次要指标

Outcome:

Total dosage of sufentanil during operation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后6 h及24 h视觉模拟疼痛评分(VAS)

指标类型:

主要指标

Outcome:

The visual analogue pain score ( VAS ) at 6 h and 24 h after operation was recorded.

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 25 years
最大 Max age 60 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

复苏室护士采用随机数字表法产生

Randomization Procedure (please state who generates the random number sequence and by what method):

The nurses in the resuscitation room were generated by random number table method.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

单盲(对受试者隐藏分组),对评估者隐藏分组。

Blinding:

Single blind ( hidden group for subjects ), hidden group for evaluators.

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case record form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-12-04 08:31:54